Activating the ligands of both IGF-1R and ErbB3 promotes ovarian cancer cell proliferation and pro-survival signaling activation, whereas the dual blocking of IGF-1R and ErbB3 enhances the efficacy of relevant chemotherapies [37]. Here, IGF1R is linked to ovarian cancer.